Irbesartan Ipca Laboratories Uk

Irbesartan, the active ingredient in Irbesartan Ipca Laboratories Uk, is an Angiotensin II receptor blocker presented as a tablet for oral use. It treats high blood pressure and helps protect kidney function in patients with diabetic kidney disease. GNH USA supplies Irbesartan Ipca Laboratories Uk as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an angiotensin II receptor blocker that acts on the renin‑angiotensin system to control blood pressure and renal outcomes.

- Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk in adults. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Cardiovascular risk reduction: used as part of therapy to lower the chance of stroke and heart attack in hypertensive patients.

Irbesartan is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: feeling light‑headed, especially after the first doses. - Headache: mild to moderate intensity. - Fatigue: unusual tiredness without exertion. - Upper respiratory tract infection: cold‑like symptoms. - Hyperkalemia: elevated blood potassium levels. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat, which can be life‑threatening. - Acute renal failure: sudden loss of kidney function, particularly in patients with pre‑existing renal disease. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatotoxicity: liver injury presenting with jaundice or elevated enzymes. - Myocardial infarction: rare reports of heart attack. - Anaphylactic reaction: severe allergic response requiring emergency care.

Before initiating Irbesartan, clinicians should evaluate several safety factors.

- Monitor blood pressure: adjust dose to achieve target levels. - Assess renal function: check serum creatinine and potassium before and during therapy. - Avoid in severe hepatic impairment: use only if benefits outweigh risks. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Drug interactions: review concomitant medications, especially potassium‑sparing agents. - Store at room temperature: keep in the original container, protect from moisture and light.

Irbesartan can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Potassium‑sparing diuretics: increase risk of hyperkalemia. - ACE inhibitors: additive risk of angioedema and renal dysfunction. - Aliskiren in diabetic patients: heightened renal adverse events. - NSAIDs: may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Lithium: Irbesartan can raise lithium concentrations, risking toxicity. - Cyclosporine: may cause increased serum creatinine. - Thiazide diuretics: can enhance hypotensive response, requiring dose adjustment.